Through the partnership, the Sophia DDM Platform will be integrated with Agilent's research-use-only SureSelect Cancer Comprehensive Genomic Profiling (CGP) Assay Kit.

The integration will enable clinical researchers to accurately identify multiple biomarkers, lowering the risk of missing important information in cancer samples, Sophia Genetics said, adding that the partnership brings together the companies' strengths in analytics and next-generation sequencing (NGS) assay development to facilitate novel approaches to cancer research.

Sophia Genetics added that it is tailoring its analytics to work with Agilent's target enrichment technology so that users have access to an advanced solution that allows multiple tumor markers to be detected.

With the Sophia DDM Platform, users will have an integrated solution with reporting tools that go beyond simple readouts and are aligned with the information and input from the latest guidelines and clinical trials reflecting relevant biomarkers, Sophia Genetics added.